Nitrofurantoin Agepha (Nitrofurantoin)

Nitrofurantoin interferes with bacterial enzyme systems that are essential for carbohydrate metabolism and cell‑wall synthesis. By inhibiting these flavoprotein enzymes, the drug disrupts bacterial growth and leads to bacterial death, especially within the urinary tract where the drug concentrates.

The dosage regimen for Nitrofurantoin Agepha is determined by the prescribing clinician based on the patient’s age, renal function, severity of infection, and local treatment guidelines. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

The pregnancy category for nitrofurantoin is listed as unknown, and safety data are limited. It should be used in pregnancy only when the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding, and the prescriber should evaluate the risk‑benefit balance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

Both nitrofurantoin and trimethoprim‑sulfamethoxazole are oral agents for uncomplicated urinary tract infections, but they have different resistance patterns and safety profiles. Nitrofurantoin achieves high urinary concentrations and is less likely to cause systemic side effects, whereas trimethoprim‑sulfamethoxazole has broader tissue distribution but may be associated with allergic reactions and hematologic effects.

Nitrofurantoin Agepha should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and heat. Keep the product out of reach of children and avoid exposure to direct sunlight.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any specific dietary considerations.

Serious adverse reactions include pulmonary toxicity such as interstitial pneumonitis, liver injury ranging from hepatitis to jaundice, and hemolytic anemia in individuals with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency. Patients should seek immediate medical attention if they experience shortness of breath, persistent cough, yellowing of the skin or eyes, or dark urine.

Nitrofurantoin Agepha should be avoided in patients with severe renal impairment (creatinine clearance <60 mL/min), known hypersensitivity to nitrofurantoin or other nitrofurans, and in individuals with G6PD deficiency due to the risk of hemolysis. Caution is also advised for pregnant women unless clearly indicated.